United States Cellular Reports Q2 Earnings

1 Mins read

United States Cellular, a wireless phone company, has announced its second-quarter earnings, falling short of analysts’ expectations. However, the company has witnessed higher revenue during this period.

Strategic Alternatives Considered for UScellular

The boards of directors of Telephone and Data Systems and United States Cellular have initiated discussions on exploring strategic alternatives for UScellular, leading to a temporary halt in premarket trading of UScellular shares at $17.50.

Quarterly Performance

In Q2, United States Cellular recorded earnings of $5 million, or 5 cents per share. This figure is lower than the earnings of $21 million, or 25 cents per share, reported in the same period last year. Analysts surveyed by FactSet were anticipating earnings of $17 million, or 9 cents per share.

The company’s revenue for the quarter totaled $957 million, compared to $1.03 billion in the previous year and the projected $993 million by analysts.

Customer Growth and Churn Reduction

UScellular achieved an 8% reduction in postpaid handset churn during the second quarter. Additionally, the company experienced a significant surge in Fixed Wireless customers, with a growth rate of 66% to 96,000.

Revised Revenue Guidance

The company has revised its service revenue guidance for 2023. The new estimate ranges from $3.05 billion to $3.15 billion, surpassing its earlier projection of $3.025 billion to $3.075 billion.

Related posts

Your Social Security Checks are Safe

2 Mins read
Don’t worry, the impending federal government shutdown will not put your monthly Social Security checks in jeopardy. This is certainly a relief…

European Stocks Experience Decrease

1 Mins read
The European stock market saw a decline on Friday, with the Stoxx Europe 600 index finishing down 0.31% at 453.26. Individual Index…

Positive Results for Cancer-Drug Combination in Bladder Cancer Study

1 Mins read
A recent Phase 3 study conducted by Merck & Co., Seagen, and Astellas Pharma has achieved its primary goals in certain patients…

Leave a Reply

Your email address will not be published. Required fields are marked *